About harrow - HROW
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Branded and ImprimisRx. The Branded segment includes activities of the company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain branded products. The ImprimisRx segment represents activities in the company’s ophthalmology-focused pharmaceutical compounding business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.
HROW At a Glance
Harrow, Inc.
1A Burton Hills Boulevard
Nashville, Tennessee 37215
| Phone | 1-615-733-4730 | Revenue | 272.30M | |
| Industry | Pharmaceuticals: Major | Net Income | -5,139,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 36.415% | |
| Fiscal Year-end | 12 / 2026 | Employees | 373 | |
| View SEC Filings |
HROW Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 6.615 |
| Price to Book Ratio | 34.783 |
| Price to Cash Flow Ratio | 41.06 |
| Enterprise Value to EBITDA | 34.425 |
| Enterprise Value to Sales | 7.271 |
| Total Debt to Enterprise Value | 0.127 |
HROW Efficiency
| Revenue/Employee | 730,034.853 |
| Income Per Employee | -13,777.48 |
| Receivables Turnover | 2.456 |
| Total Asset Turnover | 0.686 |
HROW Liquidity
| Current Ratio | 2.199 |
| Quick Ratio | 2.058 |
| Cash Ratio | 0.757 |
HROW Profitability
| Gross Margin | 75.052 |
| Operating Margin | 14.179 |
| Pretax Margin | -0.633 |
| Net Margin | -1.887 |
| Return on Assets | -1.294 |
| Return on Equity | -8.418 |
| Return on Total Capital | -1.688 |
| Return on Invested Capital | -1.709 |
HROW Capital Structure
| Total Debt to Total Equity | 480.448 |
| Total Debt to Total Capital | 82.772 |
| Total Debt to Total Assets | 62.184 |
| Long-Term Debt to Equity | 478.757 |
| Long-Term Debt to Total Capital | 82.481 |